Antios Therapeutics
OverviewSuggest Edit
Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. The Company is focused on the development of its lead oral drug candidate for a potentially curative treatment of HBV infections.
| Type | Private | |
| Founded | 2018 | |
| HQ | Atlanta, GA, US | Map |
| Website | antiostherapeutics.com |
Recent NewsAll News
- Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)
- Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV
- Antios Therapeutics and Assembly Biosciences Announce Clinical Collaboration Agreement to Evaluate the Combination of ATI-2173 and Vebicorvir in Patients with Chronic Hepatitis B Virus Infection
- Antios Therapeutics to Participate in H.C. Wainwright 2nd Annual Hepatitis B Virus Conference
Latest Updates
| Employees (est.) (Nov 2021) | 19 | |
| Cybersecurity rating | B | More |
Key People/Management at Antios Therapeutics
Greg Mayes
Chief Executive Officer
Arbutus Biopharma
Former Chief Operating Officer
Doug Mayers
Chief Medical Officer
Tamra Adams
Chief Financial Officer
Katie Laessig
Senior Vice President, Global Regulatory Affairs
Karen Fusaro
Senior Vice President, Clinical Operations
Antios Therapeutics Office Locations
Antios Therapeutics has an office in Atlanta
Atlanta, GA, US (HQ)
P.O. Box 12260
Antios Therapeutics Financials and Metrics
Summary Metrics
Founding Date | 2018 |
Antios Therapeutics total Funding | $25 m |
Antios Therapeutics latest funding size | $25 m |
Time since last funding | 3 years ago |
Antios Therapeutics investors | Fonds de solidarité FTQ, Domain Associates, Georgia Research Alliance, CAM Capital, Lumira Ventures |
Antios Therapeutics's latest funding round in November 2018 was reported to be $25 m. In total, Antios Therapeutics has raised $25 m
Antios Therapeutics Cybersecurity Score
Antios Therapeutics Online and Social Media Presence
Antios Therapeutics's Trends
Antios Therapeutics News and Updates
November 15, 2021
Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)
MENDHAM, N.J. and ROME, Nov. 15, 2021 /PRNewswire/ -- Antios Therapeutics, Inc. ("Antios"), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), and IRBM, a drug discovery and early development research institute and...
November 03, 2021
Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV
MENDHAM, N.J., Nov. 3, 2021 /PRNewswire/ -- Antios Therapeutics, Inc. ("Antios"), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), today announced the successful closing of a $75 million Series B-1 financing. The...
October 19, 2021
Antios Therapeutics and Assembly Biosciences Announce Clinical Collaboration Agreement to Evaluate the Combination of ATI-2173 and Vebicorvir in Patients with Chronic Hepatitis B Virus Infection
MENDHAM, N.J., and SOUTH SAN FRANCISCO, Calif., Oct. 19, 2021 /PRNewswire/ -- Antios Therapeutics, Inc. and Assembly Biosciences, Inc. (Nasdaq: ASMB) today announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination treatment in...
October 07, 2021
Antios Therapeutics to Participate in H.C. Wainwright 2nd Annual Hepatitis B Virus Conference
MENDHAM, N.J., Oct. 7, 2021 /PRNewswire/ -- Antios Therapeutics, Inc. ("Antios"), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), today announced that Chief Executive Officer, Gregory Mayes and Chief Medical...
September 22, 2021
Antios Therapeutics Announces Presentation at ICE-HBV Toronto Annual Symposium in Conjunction with the International HBV Meeting
MENDHAM, N.J., Sept. 22, 2021 /PRNewswire/ -- Antios Therapeutics, Inc. ("Antios") today announced that Douglas Mayers, M.D., Chief Medical Officer and Co-Founder of Antios, will be giving a presentation on ATI-2173, an investigational liver-targeting Active Site Polymerase Inhibitor...
August 10, 2021
Antios Therapeutics Appoints Catherine Coffey Ross as VP, Medical Affairs
ATLANTA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. (“Antios”) today announced the appointment of Catherine Coffey Ross as Vice President, Medical Affairs. Ms. Coffey Ross’ appointment was driven by the significant progress of the Company’s lead asset, ATI-2173, a unique Active Si…
Antios Therapeutics Frequently Asked Questions
When was Antios Therapeutics founded?
Antios Therapeutics was founded in 2018.
Who are Antios Therapeutics key executives?
Antios Therapeutics's key executives are Greg Mayes, Arbutus Biopharma and Doug Mayers.
How many employees does Antios Therapeutics have?
Antios Therapeutics has 19 employees.
Who are Antios Therapeutics competitors?
Competitors of Antios Therapeutics include Dexa Medica, Insud Pharma and Mochida Pharmaceutical.
Where is Antios Therapeutics headquarters?
Antios Therapeutics headquarters is located at P.O. Box 12260, Atlanta.
Where are Antios Therapeutics offices?
Antios Therapeutics has an office in Atlanta.
How many offices does Antios Therapeutics have?
Antios Therapeutics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies